Drugs / NG101m
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04373785 | Jan 2027 → Jul 2030 expected | glioblastoma | NeuGATE Theranostics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG101m | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04373785 ↗ |
| Route | Oral | “Oral NG101m capsule continuously twice daily.” NCT04373785 ↗ |